AbstractPurpose: Baseline neutrophil count may predict overall survival (OS) in patients with locally advanced...
Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Int J Radiat Oncol Biol Phys
AbstractAflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in the...
Posté par : Mme. Aurélia MEURISSE, Pr. Franck BONNETAIN
Nom de la revue : Int J Oncol .
ABSTRACTBACKGROUND:Two main therapies, pazopanib and sunitinib, are used in the first-line settingfor metastatic renal...
Posté par : , Mme. Joëlle FRITZSCH, Dr. Sophie PAGET-BAILLY, , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Health and Quality of Life Outcomes
AbstractObjective: To evaluate the effects of switching from prednisone (P) to dexamethasone (D) at asymptomatic...
Posté par : Mme. Julie HENRIQUES, Pr. Franck BONNETAIN
Nom de la revue : BJU Int
AbstractThe objective of this study was to assess the psychometric properties of the French version of the Supportive...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : European Journal of Cancer Care
AbstractPurpose The inclusion of patient-reported outcome (PRO) questionnaires in prognostic factor analyses in...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Quality of Life Research
ABSTRACTIntroduction While there is mounting evidence of the independent prognostic value of patient-reported outcomes...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : BMJ Open
AbstractBACKGROUND:The incidence of anal squamous cell carcinoma has been increasing markedly in the past few decades....
Posté par : Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol
Letter to editor.LINK
Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : European Journal of Cancer
ABSTRACTPurpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III...
Posté par : Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN
Nom de la revue : Journal of Clinical Oncology
BACKGROUND:RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western...
Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Nom de la revue : Ann Oncol
ABSTRACTBackground and objective: Health-related quality of life (HRQoL) has become one relevant and...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Computer Methods and Programs in Biomedicine
With advances in breast cancer (BC) gene panel testing, risk counseling has become increasingly complex, potentially...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : International Journal of Environmental Research and Public Health
AbstractBACKGROUND:Current prognostic systems for myelodysplastic syndromes (MDS) are based on clinical, pathologic, and...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Cancer
AbstractBackgroundWe studied the relationship between intermediate criteria and overall survival (OS) in metastatic...
Posté par : Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN
Nom de la revue : Clinical Colorectal Cancer
Advances in cancer care delivery require revision and further development of questionnaires assessing patients’...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : European Journal of Cancer Care
AbstractBackground The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a poor...
Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer
Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for...
Posté par : , Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Nom de la revue : JNCI J Natl Cancer Inst
Since the MOSAIC study, oxaliplatin-based adjuvant chemotherapy has been the standard treatment of stage III colon...
Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Annals of Oncology
AbstractTraditionally, the efficacy of cancer treatment in patients with advance or metastatic disease in clinical...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Annals of Oncology
ABSTRACTIntroduction: Intermediate endpoints are often used as primary endpoints instead of overall survival (OS) in...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Expert Review of Anticancer Therapy
Background:To assess the efficacy of a patient educational program built according to guidelines that aims at reducing...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : British Journal of Cancer
Background Nab-paclitaxel plus gemcitabine has become a standard treatment regimen in patients with metastatic...
Posté par : Mme. Aurélia MEURISSE, Pr. Franck BONNETAIN
Nom de la revue : Lancet Gastroenterology Hepatology
BackgroundEven if a large majority of out-of-hospital cardiac arrest (OHCA) survivors appear to have a good neurological...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Resuscitation
La mesure de la qualité de vie relative à la santé des personnes traitées pour un cancer se développe. Ce nouvel...
Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Mme. Joëlle FRITZSCH,
Nom de la revue : La revue de l'infirmière
RésuméLes données dans la littérature concernant les parcours de soins des patients atteints de cancer du pancréas...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Bulletin du Cancer
Background: Medical progress and the lifestyle modification have prolonged life expectancy, despite the development of...
Posté par : , Pr. Franck BONNETAIN
Nom de la revue : Trials
AbstractBackground: Frailty is highly prevalent in elderly people. While significant progress has been made to...
Posté par : Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY, , Pr. Franck BONNETAIN
Nom de la revue : BMC Geriatrics
AbstractBackground: Pancreatic adenocarcinoma (PDAC) incidence is increasing worldwide. Several studies have shown...
Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : BMC Cancer
Measures of health-related quality of life (HRQOL) and other patient-reported outcomes generate important data...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Lancet Oncology
Docetaxel, cisplatin, and 5-fluorouracil (DCF) significantly improved overall survival in metastatic gastroesophageal...
Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY
Nom de la revue : Cancer Medecine
Background: The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better...
Posté par : Dr. Dewi VERNEREY, , Pr. Franck BONNETAIN
Nom de la revue : British Journal of Cancer
In first-line metastatic colorectal cancer (mCRC), baseline prognostic factors allowing death risk and treatment...
Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : International Journal of Cancer
Our aim was to review the studies which assessed potential surrogate endpoints for overall survival (OS) in breast...
Posté par : Pr. Franck BONNETAIN,
Nom de la revue : Breast
In the Intergroupe Francophone de Cancérologie Thoracique 0501 trial the carboplatinpaclitaxel chemotherapy increased...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : European Respiratory Journal
Background: Even though the perioperative chemotherapy improves the overall survival (OS) compared to surgery alone in...
Posté par : Dr. Sophie PAGET-BAILLY, , Pr. Franck BONNETAIN
Nom de la revue : European Journal of Surgical Oncology
AbstractGlioblastoma is the most common malignant brain tumor in adults. Baselinehealth-relatedquality of life (HRQoL)...
Posté par : , Dr. Dewi VERNEREY, , Pr. Franck BONNETAIN
Nom de la revue : Cancer Medicine
PurposeWe previously showed that a sequential chemotherapy with dose-dense oxaliplatin (FOLFOX7)and irinotecan (FOLFIRI;...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : PLOS ONE
OBJECTIVES: The objective of this study was to explore the association between health-related quality of life (HRQoL)...
Posté par : , Pr. Franck BONNETAIN
Nom de la revue : BMJ Open
09
May, 2016
OBJECTIVES: We conducted a prospective study approved by the local ethics committee to determine the impact of a...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Annales pharmaceutiques françaises
IMPORTANCE In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and the efficacy of...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : JAMA
Health-related quality of life (HRQOL) in cancer research is critical to more comprehensively evaluate patients’...
Posté par : Pr. Franck BONNETAIN, ,
Nom de la revue : Journal of Clinical Oncology
AbstractBackground: Health-related quality of life (HRQoL) is recognized as a component endpoint for cancer...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : BMC Cancer
Background: Deficient mismatch repair (dMMR) colon cancer (CC) is reportedly resistant to 5-fluorouracil (5FU) adjuvant...
Posté par : , Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : JNCI Journal of the National Cancer Institure
AbstractBACKGROUND:We investigated whether the health-related quality of life (HRQoL) score is a prognostic factor for...
Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : EJC
Purpose Eastern Cooperative Oncology Group Performance Status (ECOG-PS) is currently an important parameter in the...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Quality of Life Research
AbstractPURPOSE:The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant...
Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : JCO
AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...
Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Lancet Oncol
Abstract Background: Baseline prognostic biomarkers stratifying treatmentstrategies in first-line metastatic...
Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue :
BACKGROUND:A randomized multicenter phase II trial was conducted to assess the sequential treatment strategy using...
Posté par : Pr. Franck BONNETAIN, , Dr. Sophie PAGET-BAILLY
Nom de la revue : PlosOne
AbstractOverall survival (OS) has been considered as the most relevant primary endpoint but trials using OS often...
Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Expert Review of Anticancer Therapy